Selinexor potentiates NK cell activation against multiple myeloma. (PubMed, Clin Exp Immunol) - Sep 27, 2026 - "These data reveal that selinexor selectively disrupts the NKG2A:HLA-E immune checkpoint axis in MM and enhances NK cell activation and ADCC against MM cells. These findings provide a mechanistic rationale for investigating combinations of selinexor with approved therapeutic antibodies in MM and suggest that treatment timing may be an important consideration in the design of combination regimens."
IO biomarker • Journal • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology • HLA-E • IFNG • IL6 • KLRC1 • XPO1
|
|
Aidan Haslam; Ben M Amram; Charlotte E Brookes; Christopher J Walker; Daniel T Harding; Georgia Francis; Graham McIlroy; Guy Pratt; Jack G Fisher; Lara V Graham; Laura G Bartlett; Mark S Cragg; Matthew D Blunt; Nancy Gudgeon; Salim I Khakoo; Sarah Dimeloe; Trinayan Kashyap
|